Israel Develops Cancer Vaccine

It is no secret that the field of medical research is highly developed in Israel, and that in recent years Israeli scientists and doctors have come out with a number of innovations that are helping to alleviate suffering around the world (for example, state-of-the-art surgical lasers). The latest innovation is a vaccine that targets cancer cells.

In a breakthrough development, the Israeli company Vaxil BioTherapeutics has formulated a therapeutic cancer vaccine, which is now in clinical trials at Hadassah University Medical Center in Jerusalem. If all goes well, the vaccine could be available in about six years to administer on a regular basis. Reports are that it will not only help treat cancer, but will also keep the disease from recurring.

The vaccine is being tested against a type of blood cancer called multiple myeloma. If the substance works as hoped—and it looks like all arrows are pointing that way—its technology could be applied to 90 percent of all known cancers, including prostate and breast cancer, solid and non-solid tumors.

The company’s lead product, ImMucin, activates the immune system by “training” T-cells—the immune cells that protect the body—by searching out and destroying cells that display a specific molecule (or marker) called MUC1. MUC1 is typically found only in cancer cells and not in healthy cells. The T-cells don’t attack any cells without MUC1, meaning that, unlike traditional cancer treatments, there are no side effects. More than 90% of different cancers have MUC1 in their cells, which indicates the potential for this amazing vaccine [information gathered from].

Thank God for this much-needed breakthrough, and let us pray that the treatment will be ready much sooner than the six years that have been predicted.

“Praise the Lord, O my soul, and forget not all his benefits—who forgives all your sins and heals all your diseases…” (Psalm 103:2-3).